NFE2L2 rs35652124C>T polymorphism predicts Grade 4 neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and fluorouracil chemotherapy: results from exploratory and validation cohorts.
Saved in:
| Title: | NFE2L2 rs35652124C>T polymorphism predicts Grade 4 neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and fluorouracil chemotherapy: results from exploratory and validation cohorts. |
|---|---|
| Authors: | Nomura H; Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, Kyoto, 606-8507, Japan. hisanaga0726@kuhp.kyoto-u.ac.jp.; Department of Pharmacy, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. hisanaga0726@kuhp.kyoto-u.ac.jp., Suzuki T; Department of Clinical Pharmacology & Genetics, University of Shizuoka, Shizuoka, Shizuoka, Japan., Kojima T; Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Chiba, Japan., Itoh K; Department of Clinical Pharmacology & Genetics, University of Shizuoka, Shizuoka, Shizuoka, Japan., Tsuji D; Department of Clinical Pharmaceutics, University of Shizuoka, Shizuoka, Shizuoka, Japan. |
| Source: | Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2026 Mar 06; Vol. 96 (1). Date of Electronic Publication: 2026 Mar 06. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1432-0843 |
|---|---|
| DOI: | 10.1007/s00280-026-04866-0 |
